July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Laquinimod effectively inhibits development of EAU and its associated immune effector responses
Author Affiliations & Notes
  • Biying Xu
    Laboratory of Immunology, NEI/NIH, Bethesda, Maryland, United States
  • Xiuzhi Jia
    Laboratory of Immunology, NEI/NIH, Bethesda, Maryland, United States
  • Jihong Tang
    Laboratory of Immunology, NEI/NIH, Bethesda, Maryland, United States
  • Rachel R Caspi
    Laboratory of Immunology, NEI/NIH, Bethesda, Maryland, United States
  • Igal Gery
    Laboratory of Immunology, NEI/NIH, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Biying Xu, None; Xiuzhi Jia, None; Jihong Tang, None; Rachel Caspi, None; Igal Gery, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 792. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Biying Xu, Xiuzhi Jia, Jihong Tang, Rachel R Caspi, Igal Gery; Laquinimod effectively inhibits development of EAU and its associated immune effector responses. Invest. Ophthalmol. Vis. Sci. 2019;60(9):792. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Experimental autoimmune uveitis (EAU), an animal model for human uveitis, serves as a platform for testing potential therapeutic compounds. Here, we tested the efficacy of laquinimod (LAQ), previously shown to be an aryl hydrocarbon receptor antagonist, to suppress EAU and related immune responses.

Methods : EAU was induced in C57BL/6J mice by immunization with 300ug of IRBP peptide p651-670, in CFA. LAQ, provided by TEVA, at a dose of 25mg/Kg, or PBS for control, were administered daily by oral gavage. Mice were treated either from day 0 or day 7 post immunization (prevention and reversal regimens, respectively). EAU progression was monitored by fundoscopy and confirmed by histology. Immune responses to p651-670 were assessed by antigen specific proliferation and production of IFN-gamma and IL-17, which were measured by ELISA or intracellular cytokine staining and flow cytometry. FoxP3 expression by CD4+ lymphocytes was determined by flow cytometry. Two-tailed Student's t-test and two-way ANOVA were used for statistical analysis.

Results : Treatment with LAQ from day 0 completely inhibited EAU induction and the associated proliferative and cytokine responses to p651-670, both by ELISA and by intracellular staining. Mice treated with LAQ from day 7 developed reduced EAU and related immune responses. Although responses in mice treated with LAQ from day 7 were only partially suppressed, in all assays responses of the treated mice were significantly below their controls. Treatment with LAQ increased slightly the proportion of FoxP3+ cells in the spleen and draining lymph nodes, and significantly elevated the proportion of Foxp3+ T cells in inflamed eyes.

Conclusions : Prevention treatment with LAQ completely inhibited the induction of EAU and its associated immune effector responses. Further, even reversal treatment regimen (starting on day 7 post immunization) significantly suppressed these responses and lowered EAU scores.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×